Myriad Genetics Advances Prostate Cancer Biomarker Through SOPHiA GENETICS Collaboration

Key Points

• Myriad Genetics is partnering with SOPHiA GENETICS to advance its prostate cancer-specific genomic instability score, or PrGIS, in precision oncology work involving AstraZeneca.
• Myriad developed PrGIS to assess chromosomal instability associated with homologous recombination deficiency in prostate cancer.
• Myriad’s MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for a potential prostate cancer indication.
• SOPHiA GENETICS plans to incorporate PrGIS into a decentralized companion diagnostic solution intended to support local laboratory testing.
• Myriad will present additional PrGIS research, co-authored with AstraZeneca, at ESMO 2026. Full findings remain subject to the conference embargo.

Myriad Genetics (NASDAQ: MYGN) is expanding development of its prostate cancer biomarker technology through a new collaboration with SOPHiA Genetics (NASDAQ: SOPH). The partnership aims to advance PrGIS in clinical trials and support potential companion diagnostic solutions that could help identify patients for precision oncology medicines.

Myriad’s PrGIS Targets DNA-Repair Deficiency in Prostate Cancer

Myriad developed PrGIS as a prostate cancer-specific biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency, or HRD. The companies describe HRD as an emerging prognostic and predictive biomarker in prostate cancer.

PrGIS is intended to support patient stratification in clinical trials and the development of companion diagnostics. The announcement does not establish an approved prostate cancer use or provide numerical validation results.

MyChoice CDx Development Extends Beyond Ovarian Cancer

Myriad’s proprietary MyChoice CDx test will generate the PrGIS score. The test is currently available as a companion diagnostic in ovarian cancer and is being advanced for prostate cancer as a new indication.

For Myriad, the collaboration creates an opportunity to extend its existing diagnostic technology into another cancer setting. Whether that development results in a new clinical indication will depend on validation and further development.

SOPHiA GENETICS Plans Local Testing Through Its Global Network

SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic that incorporates Myriad’s PrGIS technology.

The approach aims to make testing available through local laboratories rather than relying solely on a centralized model. SOPHiA GENETICS says its cloud-based platform connects more than 1,000 institutions in over 75 countries. That network represents potential reach, not confirmed PrGIS deployment at every institution.

ESMO 2026 Research Will Add Biomarker Evidence

Myriad plans to present PrGIS research co-authored with AstraZeneca at ESMO 2026. The findings are expected to further characterize the biomarker and support its validation.

Full data will become available after the conference embargo. Until then, the announcement does not disclose the study population, performance measures or treatment-response findings.

Investor Takeaway: Myriad Gains a Development and Distribution Opportunity

For MYGN investors, the partnership combines Myriad’s proprietary biomarker technology with a potential international pathway for local testing. It also highlights the company’s companion diagnostic development work with biopharmaceutical partners.

The commercial impact remains unquantified. The announcement does not disclose financial terms, revenue-sharing arrangements, launch timing or a regulatory submission schedule. The next meaningful evidence will be the ESMO findings, progress in clinical validation and advancement of the proposed companion diagnostic solutions.